Table 1

Selected RCTs for systemic chemotherapy of advanced colorectal cancer
Author, year Pat. [n] Treatment regimen Median PFS [months] Median OS [months]
DeGramont, 2000 [15] 210 FOLFOX4 9.0 16.2
Giacchetti, 2000 [16] 100 FOLFOX 8.7 19.4
Douillard, 2000 [17] 199 FOLFIRI 6.7 17.4
Saltz, 2000 [18] 226 IFL 7.0 14.8
Tournigand, 2003 [19] 109 FOLFIRI/FOLFOX6 14.2 21.5
Hurwitz, 2004 [20] 402 IFL/bevacizumab 10.6 20.3
Goldberg, 2006 [21] 154 FOLFOX4 9.7 19.0
Falcone, 2007 [13] 122 FOLFOXIRI 9.8 22.6
Fuchs, 2008 [22,23] 57 FOLFIRI/bevacizumab 11.2 28.0
Saltz, 2008 [24] 699 FOLFOX4/bevacizumab 9.4 21.3
Hecht, 2009 [25] 823 FOLFOX/FOLFIRI/bev 11.4 24.5
+ panitumumab 10.0 19.4
Tebbutt, 2010 [26] 157 capecitabine/bevacizumab 8.5 -
Stathopoulos, 2010 [27] 114 IRI/5-FU/FA/bevacizumab - 22.0
108 IRI/5-FU/FA - 25.0
Douillard, 2010 [28] 1183 FOLFOX4/panitumumab 9.6 23.9

Glockzin et al.

Glockzin et al. BMC Cancer 2013 13:67   doi:10.1186/1471-2407-13-67

Open Data